Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $9.9 million.

  • Arrowhead Pharmaceuticals' Gains from Investment Securities rose 8996363.64% to $9.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $10.7 million, marking a year-over-year increase of 49173.37%. This contributed to the annual value of $814000.0 for FY2025, which is 12174.15% up from last year.
  • As of Q4 2025, Arrowhead Pharmaceuticals' Gains from Investment Securities stood at $9.9 million, which was up 8996363.64% from $733000.0 recorded in Q3 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Gains from Investment Securities registered a high of $20.9 million during Q1 2021, and its lowest value of -$6.8 million during Q3 2024.
  • For the 5-year period, Arrowhead Pharmaceuticals' Gains from Investment Securities averaged around $2.6 million, with its median value being $733000.0 (2025).
  • As far as peak fluctuations go, Arrowhead Pharmaceuticals' Gains from Investment Securities plummeted by 22823.19% in 2022, and later surged by 8996363.64% in 2025.
  • Quarter analysis of 5 years shows Arrowhead Pharmaceuticals' Gains from Investment Securities stood at $3.5 million in 2021, then plummeted by 228.23% to -$4.4 million in 2022, then surged by 77.46% to -$999000.0 in 2023, then skyrocketed by 101.1% to $11000.0 in 2024, then surged by 89963.64% to $9.9 million in 2025.
  • Its Gains from Investment Securities was $9.9 million in Q4 2025, compared to $733000.0 in Q3 2025 and $70000.0 in Q1 2025.